RIT Biotech Company Limited is a newly established central radiopharmacy designed to provide the best quality service in Hong Kong.
We are dedicated and committed to serving the detection drug industry by providing innovative radiopharmaceuticals and improving quality services to nuclear medicine and clinical oncology specialties.
RIT Biotech is the holder of a Poison Vendor (ASP) license granted by the Department of Health of the Hong Kong Special Administrative Region. This condition is based on guidelines developed by the European Association of Nuclear Medicine (EANM) to the extent that RIT Biotech fully complies with the requirements of “Current Good Pharmaceutical Practice (Part A)” (cGRPP) in in vivo drug preparation. Through cGRPP's production and operation practices, we ensure that we provide the best quality assurance and meet all the requirements of the Pharmacist and Poisons Ordinance, Chapter 138 of Hong Kong.
Initially, the cGRPP license held by RIT Biotech was the first license in the field of SPECT / conventional nuclear medicine radiotherapy and clinical oncology.
Chief Executive Officer
Mr. Clement Tam - M.Sc. B.Sc. in Engineering
20+ years’ senior management experience with multinational corporations in diverse industries
General Manager
Mr. Nelson To - M.B.A. B.Sc. in Chemistry
10 years Sales & Marketing experience on radioactive consumables and radiopharmaceuticals
Pharmacist-in-Charge
Mr. Ringo Leung - M.Pharm. MRPharmS
Responsible for radiopharmaceutical compounding procedures, major licensing applications including cGRPP
